Investor FAQs
Our official name is Kronos Bio, Inc.
We are headquartered in San Mateo, Calif., and we have a research facility in Cambridge, Mass.
Our mailing address is:
1300 So. El Camino Real
Suite 300
San Mateo, CA 94402
Our company was incorporated in June 2017.
Our initial public offering was on October 8, 2020.
Kronos Bio common stock is traded on the Nasdaq Global Select Market under the symbol KRON.
We do not offer a direct purchase plan for investors. You may purchase Kronos Bio’s common stock through a licensed securities broker.
Our transfer agent is:
AST, LLC
Attn: Customer Service
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
info@astfinancial.com
If your shares are held in street name (i.e., through your brokerage account), you must contact your broker.
If your shares held directly by you in your name, please contact our transfer agent:
AST, LLC
Attn: Customer Service
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
info@astfinancial.com
We do not anticipate paying cash dividends on its common stock for the foreseeable future.
Our independent auditor is:
Ernst & Young LLP
560 Mission St., Ste 1600
San Francisco, CA 94105
Our outside legal counsel is:
Cooley LLP
101 California Street, 5th Floor
San Francisco, CA 94111
Our fiscal year end is December 31.
Our SEC filings, when available, are listed on the SEC's web site, www.sec.gov. You may also find our filings in the SEC Filings section of our website.
Please email investor@kronosbio.com for assistance with investor relations questions.